KDRA calls for various supportive measures for the timely development of new drugs

In the midst of the growing criticism from the domestic pharmaceutical industry over the government policy to discourage the prescription of high-priced drugs through incentive system, the Korea Drug Research Association (KDRA) has asserted that the introduction of incentive system is likely to curtail the R&D outlays of the domestic drug firms, even though it may contribute to better finance s...